Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: an in silico and in vitro approach. Issue 4 (17th March 2023)
- Record Type:
- Journal Article
- Title:
- Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: an in silico and in vitro approach. Issue 4 (17th March 2023)
- Main Title:
- Development of thiazole-appended novel hydrazones as a new class of α-amylase inhibitors with anticancer assets: an in silico and in vitro approach
- Authors:
- Chahal, Sandhya
Punia, Jyoti
Rani, Payal
Singh, Rajvir
Mayank,
Kumar, Parvin
Kataria, Ramesh
Joshi, Gaurav
Sindhu, Jayant - Abstract:
- Abstract : Thiazole-clubbed hydrazones exhibited in vitro α-amylase inhibitory response in the range of IC50 values from 0.23 ± 0.003 to 0.5 ± 0.0 μM. 5b was found to be the least cytotoxic and most potent α-amylase inhibitor. Abstract : Hyperamylasemia is reported to be associated with numerous chronic diseases, including diabetes and cancer. Considering this fact, we developed a series of thiazole-clubbed hydrazones. The derivatives were explored for their in vitro α-amylase inhibitory activity, which was further corroborated with their anticancer assets using a panel of cancer cells, including colon cancer (HCT-116), lung cancer (A549), and breast cancer (MDA-MB-231). To better understand pharmacokinetics, the synthetic derivatives were subjected to in silico ADMET prediction. The in vitro based biological investigation revealed that compared to the reference drug acarbose (IC50 = 0.21 ± 0.008 μM), all the synthesized compounds (5a–5aa ) exhibited in vitro α-amylase inhibitory response in the range of IC50 values from 0.23 ± 0.003 to 0.5 ± 0.0 μM. Along with this, the proliferations of the HCT-116, A549 and MDA-MB-231 cells were inhibited when treated with the synthesized compounds. Notable cancer cell growth inhibition was observed for compounds 5e, 5f and 5y, which correlated with their α-amylase inhibition. Additionally, the kinetics investigation revealed that 5b, 5e, 5f and 5y exhibit uncompetitive inhibition. 5b was found to be the least cytotoxic and most potentAbstract : Thiazole-clubbed hydrazones exhibited in vitro α-amylase inhibitory response in the range of IC50 values from 0.23 ± 0.003 to 0.5 ± 0.0 μM. 5b was found to be the least cytotoxic and most potent α-amylase inhibitor. Abstract : Hyperamylasemia is reported to be associated with numerous chronic diseases, including diabetes and cancer. Considering this fact, we developed a series of thiazole-clubbed hydrazones. The derivatives were explored for their in vitro α-amylase inhibitory activity, which was further corroborated with their anticancer assets using a panel of cancer cells, including colon cancer (HCT-116), lung cancer (A549), and breast cancer (MDA-MB-231). To better understand pharmacokinetics, the synthetic derivatives were subjected to in silico ADMET prediction. The in vitro based biological investigation revealed that compared to the reference drug acarbose (IC50 = 0.21 ± 0.008 μM), all the synthesized compounds (5a–5aa ) exhibited in vitro α-amylase inhibitory response in the range of IC50 values from 0.23 ± 0.003 to 0.5 ± 0.0 μM. Along with this, the proliferations of the HCT-116, A549 and MDA-MB-231 cells were inhibited when treated with the synthesized compounds. Notable cancer cell growth inhibition was observed for compounds 5e, 5f and 5y, which correlated with their α-amylase inhibition. Additionally, the kinetics investigation revealed that 5b, 5e, 5f and 5y exhibit uncompetitive inhibition. 5b was found to be the least cytotoxic and most potent α-amylase inhibitor and was further validated by absorption and fluorescence quenching technique. … (more)
- Is Part Of:
- RSC medicinal chemistry. Volume 14:Issue 4(2023)
- Journal:
- RSC medicinal chemistry
- Issue:
- Volume 14:Issue 4(2023)
- Issue Display:
- Volume 14, Issue 4 (2023)
- Year:
- 2023
- Volume:
- 14
- Issue:
- 4
- Issue Sort Value:
- 2023-0014-0004-0000
- Page Start:
- 757
- Page End:
- 781
- Publication Date:
- 2023-03-17
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://www.rsc.org/ ↗
https://www.rsc.org/journals-books-databases/about-journals/rsc-medicinal-chemistry ↗ - DOI:
- 10.1039/d2md00431c ↗
- Languages:
- English
- ISSNs:
- 2632-8682
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8036.751550
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 27046.xml